文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

游离丙戊酸血药浓度临床药动学监测的系统综述

Clinical Pharmacokinetic Monitoring of Free Valproic Acid Levels: A Systematic Review.
PubMed 文献 · Clin Pharmacokinet · 2022-08-30

该系统综述检索了截至2021年6月的多个数据库,纳入27项研究(14项观察性研究、2项病例系列、11项病例报告),旨在确定游离丙戊酸的治疗范围、其与临床毒性/疗效的相关性及游离与总浓度不一致的预测因素。结果显示数据匮乏,仅3项研究提供20-410 μmol/L的治疗范围,低白蛋白血症是不一致的预测因素。

要点

  • 游离丙戊酸治疗范围证据有限,仅3项研究提示20-410 μmol/L。
  • 高氨血症和血小板减少分别见于游离浓度>60 µmol/L和>103.3 µmol/L。
  • 神经毒性上限可能为70 µmol/L或207.9 µmol/L,低白蛋白血症预测浓度不一致。

核心结论

  • 游离丙戊酸血药浓度临床效用数据匮乏,需高质量试验验证最佳治疗范围。

研究设计与样本

  • 系统综述检索Medline、EMBASE、CENTRAL、PsycINFO、BIOSIS Previews和CINAHL从建库至2021年6月20日。
  • 纳入评估任何接受丙戊酸并监测游离浓度的患者的随机对照试验和观察性研究。
  • 共纳入27项研究,包括14项观察性研究、2项病例系列和11项病例报告。

主要发现

  • 3项研究提供游离丙戊酸治疗范围在20至410 μmol/L之间。
  • 2项研究提示游离丙戊酸浓度高于60 µmol/L时出现高氨血症,高于103.3 µmol/L时出现血小板减少。
  • 2项研究提示神经毒性上限分别为游离丙戊酸浓度70 µmol/L和207.9 µmol/L。
  • 低白蛋白血症被确定为治疗浓度不一致的预测因素。

关键数值与推荐

  • 游离丙戊酸治疗范围:20-410 μmol/L(基于3项研究)。
  • 高氨血症相关游离浓度:>60 µmol/L(基于2项研究)。
  • 血小板减少相关游离浓度:>103.3 µmol/L(基于2项研究)。
  • 神经毒性上限:70 µmol/L或207.9 µmol/L(基于2项研究)。

临床怎么用

  • 在特定临床场景下(如低白蛋白血症),监测游离丙戊酸浓度可能有助于评估临床反应。

局限性

  • 纳入研究多为观察性研究、病例系列和病例报告,证据等级较低。
  • 游离丙戊酸治疗范围的数据匮乏,仅3项研究提供范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend therapeutic drug monitoring as a critical component of valproic acid (VPA) therapy. Due to high protein binding, the active unbound (free) portion of VPA can be misrepresented by total VPA serum levels in certain clinical scenarios. Monitoring free VPA serum levels may be warranted when assessing the clinical response to VPA therapy. OBJECTIVES: The aims were to conduct a systematic review to identify a therapeutic range for free VPA serum levels; to explore the correlation of free VPA serum levels with clinical toxicity and therapeutic benefit; and to examine predictors of discordance between free and total VPA levels. METHODS: Medline, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, BIOSIS Previews, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from the time of database inception to June 20, 2021. Randomized controlled trials and observational studies that evaluated any patient receiving VPA with free VPA level monitoring were included. RESULTS: Of 189 citations, we identified 27 relevant studies, which included 14 observational studies, two case series, and 11 case reports. Three studies provided a therapeutic range for free VPA levels between 20 and 410 μmol/L. Two studies suggested the occurrence of hyperammonemia and thrombocytopenia at free VPA serum levels above 60 µmol/L and 103.3 µmol/L, respectively. Two studies suggested an upper limit for neurotoxicity at free VPA serum levels of 70 µmol/L and 207.9 µmol/L. Hypoalbuminemia was identified as a predictor of therapeutic discordance. CONCLUSIONS: This review demonstrates a paucity of data informing the clinical utility of free VPA serum levels. Further high-quality trials are needed to validate an optimal therapeutic range for free VPA levels.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Lin K, Cao VFS, Au C, et al. Clinical Pharmacokinetic Monitoring of Free Valproic Acid Levels: A Systematic Review. Clin Pharmacokinet. 2022. PMID: 36040614. doi:10.1007/s40262-022-01171-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。